175 related articles for article (PubMed ID: 8141226)
1. Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients.
Hurteau JA; Simon HU; Kurman C; Rubin L; Mills GB
Am J Obstet Gynecol; 1994 Mar; 170(3):918-28. PubMed ID: 8141226
[TBL] [Abstract][Full Text] [Related]
2. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer.
Barton DP; Blanchard DK; Michelini-Norris B; Nicosia SV; Cavanagh D; Djeu JY
Blood; 1993 Jan; 81(2):424-9. PubMed ID: 8422462
[TBL] [Abstract][Full Text] [Related]
3. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
5. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
[TBL] [Abstract][Full Text] [Related]
6. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer.
Gastl G; Plante M; Finstad CL; Wong GY; Federici MG; Bander NH; Rubin SC
Br J Haematol; 1993 Mar; 83(3):433-41. PubMed ID: 8485049
[TBL] [Abstract][Full Text] [Related]
7. Expression of interleukin-2 receptor alpha (IL-2R alpha) mRNA and protein in advanced epithelial ovarian cancer.
Barton DP; Blanchard DK; Wells AF; Nicosia SV; Roberts WS; Cavanagh D; Djeu JY
Anticancer Res; 1994; 14(3A):761-72. PubMed ID: 8074478
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients.
Pavlidis NA; Bairaktari E; Kalef-Ezra J; Nicolaides C; Seferiadis C; Fountzilas G
Int J Biol Markers; 1995; 10(2):75-80. PubMed ID: 7561242
[TBL] [Abstract][Full Text] [Related]
9. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
10. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.
Zeimet AG; Widschwendter M; Knabbe C; Fuchs D; Herold M; Müller-Holzner E; Daxenbichler G; Offner FA; Dapunt O; Marth C
J Clin Oncol; 1998 May; 16(5):1861-8. PubMed ID: 9586902
[TBL] [Abstract][Full Text] [Related]
11. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer.
Hunter VJ; Weinberg JB; Haney AF; Soper JT; Lavin P; Metsch L; Knapp RC; Bast RC
Gynecol Oncol; 1990 Feb; 36(2):161-5. PubMed ID: 2404835
[TBL] [Abstract][Full Text] [Related]
12. Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report.
Beller U; Chachoua A; Speyer JL; Sorich J; Dugan M; Liebes L; Hayes R; Beckman EM
Gynecol Oncol; 1989 Sep; 34(3):407-12. PubMed ID: 2788602
[TBL] [Abstract][Full Text] [Related]
13. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
[TBL] [Abstract][Full Text] [Related]
14. T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies.
Chen CK; Wu MY; Chao KH; Ho HN; Sheu BC; Huang SC
J Formos Med Assoc; 1999 Jan; 98(1):24-30. PubMed ID: 10063270
[TBL] [Abstract][Full Text] [Related]
15. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
16. [A clinical evaluation of CA 125 levels in serum, ascites and pleural effusion].
Jibiki K; Demura R; Abe Y; Odagiri E; Demura H
Gan No Rinsho; 1987 Nov; 33(14):1756-62. PubMed ID: 3480363
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
18. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
19. Serum and cystic fluid levels of soluble interleukin-2 receptor-alpha in patients with epithelial ovarian tumors are correlated.
de Bruijn HW; ten Hoor KA; van der Zee AG
Tumour Biol; 1998; 19(3):160-6. PubMed ID: 9591042
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
